Yi Lin, MD, PhD, explains the potential impact the approval of idecabtagene vicleucel could bring to the multiple myeloma field.
Yi Lin, MD, PhD, an assistant professor for Oncology and Medicine at the Mayo Clinic, explains the potential impact the approval of idecabtagene vicleucel (Ide-cel) could bring to the multiple myeloma field.
Based on the data ide-cel showed in the phase 3 KarMMa study (NCT03361748), Lin says that it is likely that ide-cel will be granted approval by the FDA in 2021 for patients who have had at least 3 lines of prior therapy and have been exposed to the currently approved 3 main backbones of treatment. The 3 backbone of treatments include a protosome inhibitor, an immunomodulatory agent, and a CD38 antibody. The exciting part of this, Lin says, is that ide-cel may become the first FDA-approved chimeric antigen receptor T-cell therapy for multiple myeloma.
Lin also states that although the ide-cel indication may be for previously-treated patients, there is likely more benefit for these patients if they receive treatment earlier on in their disease course.